Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer

A. Quon; S. T. Chang; F. Chin; A. Kamaya; D. W. Dick; B. W. Loo; S. S. Gambhir; A. C. Koong

doi:10.1007/s00259-007-0630-z

Initial evaluation of ¹⁸F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer

A. Quon, S. T. Chang, F. Chin, A. Kamaya, D. W. Dick, B. W. Loo, S. S. Gambhir, A. C. Koong

Image Guided Cancer Therapy Research Program

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Abstract

Purpose: The aim of this study was to evaluate the potential of ¹⁸F-fluorothymidine (FLT) PET/CT for imaging pancreatic adenocarcinoma. Methods: This was a pilot study of five patients (four males, one female) with newly diagnosed and previously untreated pancreatic adenocarcinoma. Patients underwent FLT PET/CT, ¹⁸F-fluorodeoxyglucose (FDG) PET/CT, and contrast-enhanced CT scanning before treatment. The presence of cancer was confirmed by histopathological analysis at the time of scanning in all five patients. The degree of FLT and FDG uptake at the primary tumor site was assessed using visual interpretation and semi-quantitative SUV analyses. Results: The primary tumor size ranged from 2.5×2.8 cm to 3.5 × 7.0 cm. The SUV of FLT uptake within the primary tumor ranged from 2.1 to 3.1. Using visual interpretation, the primary cancer could be detected from background activity in two of five patients (40%) on FLT PET/CT. By comparison, FDG uptake was higher in each patient with a SUV range of 3.4 to 10.8, and the primary cancer could be detected from background in all five patients (100%). Conclusions: In this pilot study of five patients with primary pancreatic adenocarcinoma, FLT PET/CT scanning showed poor lesion detectability and relatively low levels of radiotracer uptake in the primary tumor.

Original language	English (US)
Pages (from-to)	527-531
Number of pages	5
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	35
Issue number	3
DOIs	https://doi.org/10.1007/s00259-007-0630-z
State	Published - Mar 1 2008

Keywords

FDG PET
FLT PET
Oncology
Pancreatic cancer
PET/CT

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1007/s00259-007-0630-z

Cite this

@article{8b6211517ff94180a0eb243985e748c1,

title = "Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer",

abstract = "Purpose: The aim of this study was to evaluate the potential of 18F-fluorothymidine (FLT) PET/CT for imaging pancreatic adenocarcinoma. Methods: This was a pilot study of five patients (four males, one female) with newly diagnosed and previously untreated pancreatic adenocarcinoma. Patients underwent FLT PET/CT, 18F-fluorodeoxyglucose (FDG) PET/CT, and contrast-enhanced CT scanning before treatment. The presence of cancer was confirmed by histopathological analysis at the time of scanning in all five patients. The degree of FLT and FDG uptake at the primary tumor site was assessed using visual interpretation and semi-quantitative SUV analyses. Results: The primary tumor size ranged from 2.5×2.8 cm to 3.5 × 7.0 cm. The SUV of FLT uptake within the primary tumor ranged from 2.1 to 3.1. Using visual interpretation, the primary cancer could be detected from background activity in two of five patients (40%) on FLT PET/CT. By comparison, FDG uptake was higher in each patient with a SUV range of 3.4 to 10.8, and the primary cancer could be detected from background in all five patients (100%). Conclusions: In this pilot study of five patients with primary pancreatic adenocarcinoma, FLT PET/CT scanning showed poor lesion detectability and relatively low levels of radiotracer uptake in the primary tumor.",

keywords = "FDG PET, FLT PET, Oncology, Pancreatic cancer, PET/CT",

author = "A. Quon and Chang, {S. T.} and F. Chin and A. Kamaya and Dick, {D. W.} and Loo, {B. W.} and Gambhir, {S. S.} and Koong, {A. C.}",

note = "Funding Information: The study was funded in part by The Stanford University Office of Technology Licensing.",

year = "2008",

month = mar,

day = "1",

doi = "10.1007/s00259-007-0630-z",

language = "English (US)",

volume = "35",

pages = "527--531",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer Verlag",

number = "3",

}

TY - JOUR

T1 - Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer

AU - Quon, A.

AU - Chang, S. T.

AU - Chin, F.

AU - Kamaya, A.

AU - Dick, D. W.

AU - Loo, B. W.

AU - Gambhir, S. S.

AU - Koong, A. C.

N1 - Funding Information: The study was funded in part by The Stanford University Office of Technology Licensing.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Purpose: The aim of this study was to evaluate the potential of 18F-fluorothymidine (FLT) PET/CT for imaging pancreatic adenocarcinoma. Methods: This was a pilot study of five patients (four males, one female) with newly diagnosed and previously untreated pancreatic adenocarcinoma. Patients underwent FLT PET/CT, 18F-fluorodeoxyglucose (FDG) PET/CT, and contrast-enhanced CT scanning before treatment. The presence of cancer was confirmed by histopathological analysis at the time of scanning in all five patients. The degree of FLT and FDG uptake at the primary tumor site was assessed using visual interpretation and semi-quantitative SUV analyses. Results: The primary tumor size ranged from 2.5×2.8 cm to 3.5 × 7.0 cm. The SUV of FLT uptake within the primary tumor ranged from 2.1 to 3.1. Using visual interpretation, the primary cancer could be detected from background activity in two of five patients (40%) on FLT PET/CT. By comparison, FDG uptake was higher in each patient with a SUV range of 3.4 to 10.8, and the primary cancer could be detected from background in all five patients (100%). Conclusions: In this pilot study of five patients with primary pancreatic adenocarcinoma, FLT PET/CT scanning showed poor lesion detectability and relatively low levels of radiotracer uptake in the primary tumor.

AB - Purpose: The aim of this study was to evaluate the potential of 18F-fluorothymidine (FLT) PET/CT for imaging pancreatic adenocarcinoma. Methods: This was a pilot study of five patients (four males, one female) with newly diagnosed and previously untreated pancreatic adenocarcinoma. Patients underwent FLT PET/CT, 18F-fluorodeoxyglucose (FDG) PET/CT, and contrast-enhanced CT scanning before treatment. The presence of cancer was confirmed by histopathological analysis at the time of scanning in all five patients. The degree of FLT and FDG uptake at the primary tumor site was assessed using visual interpretation and semi-quantitative SUV analyses. Results: The primary tumor size ranged from 2.5×2.8 cm to 3.5 × 7.0 cm. The SUV of FLT uptake within the primary tumor ranged from 2.1 to 3.1. Using visual interpretation, the primary cancer could be detected from background activity in two of five patients (40%) on FLT PET/CT. By comparison, FDG uptake was higher in each patient with a SUV range of 3.4 to 10.8, and the primary cancer could be detected from background in all five patients (100%). Conclusions: In this pilot study of five patients with primary pancreatic adenocarcinoma, FLT PET/CT scanning showed poor lesion detectability and relatively low levels of radiotracer uptake in the primary tumor.

KW - FDG PET

KW - FLT PET

KW - Oncology

KW - Pancreatic cancer

KW - PET/CT

UR - http://www.scopus.com/inward/record.url?scp=43349099619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43349099619&partnerID=8YFLogxK

U2 - 10.1007/s00259-007-0630-z

DO - 10.1007/s00259-007-0630-z

M3 - Article

C2 - 17960376

AN - SCOPUS:43349099619

SN - 1619-7070

VL - 35

SP - 527

EP - 531

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 3

ER -